We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Department of Justice plans to continue its investigation into anticompetitive activity in the generic drug industry, according to a senior DOJ official. Read More
The Trump administration’s fiscal 2021 budget proposal unveiled Monday seeks an increase of 4.5 percent for the FDA while cutting most other non-defense spending. Read More
The FDA confirmed that it has suspended inspections of Chinese drug manufacturing facilities until further notice in response to the coronavirus outbreak. Read More
Inventia Healthcare, a drugmaker headquartered in Mumbai, India, was slapped with a Form 483 for serious violations at its Thane, Maharashtra facility, including poor data integrity. Read More
The FDA hit a drug manufacturer in Dresden, Germany with a warning letter for serious violations, including a lack of API and stability testing. Read More
California’s State Board of Pharmacy is considering a request to revoke or suspend McKesson’s wholesale permit for “excessively” supplying controlled substances to a children’s pharmacy that are not typically distributed to pediatric patients. Read More
The Department of Justice (DOJ) has indicted a former Taro Pharmaceuticals executive for allegedly conspiring to fix numerous generic drug prices. Read More